Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DORADO-EX long-term darusentan safety extension in resistant hypertension
2006-001899-20Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind, single-arm trial of darusentan in resistant hypertension (RH) and hypertension (HTN), sponsored by Gilead Sciences. Primary endpoint: Long-term safety of darusentan. Started Sep 2006; status: completed.
02
Drugs
darusentan
03
Conditions
resistant hypertension (RH)hypertension (HTN)
Beyond the preview
Go deeper on 2006-001899-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001899-20.